Matinas BioPharma Holdings, Inc. (MTNB) intrinsic value & 10-year financials
Matinas BioPharma Holdings, Inc. (MTNB) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $2.37
- Market cap
- $13.0M
- Revenue (FY2025)
- —
- Revenue growth (10-yr CAGR)
- 39.4%
- ROIC (10-yr avg)
- -189.0%
- Free cash flow (FY2025)
- —
MTNB 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$10.3M | -$2.00 | — | — | -527.4% |
| FY2024 | — | -$24.3M | -$4.98 | — | — | -247.7% |
| FY2023 | $1.1M | -$22.9M | -$0.11 | -$15.5M | -2168.4% | -90.5% |
| FY2022 | $3.2M | -$21.0M | -$0.10 | -$20.0M | -771.3% | -60.9% |
| FY2021 | $33.3K | -$23.3M | — | -$15.5M | -74205.0% | -51.6% |
| FY2020 | $158.3K | -$22.4M | — | -$17.4M | -15288.4% | -64.8% |
| FY2019 | $89.8K | -$17.4M | — | -$14.5M | -21067.4% | -188.5% |
| FY2018 | $119.8K | -$14.1M | — | -$10.9M | -12230.9% | -371.8% |
| FY2017 | $149.7K | -$15.5M | — | -$12.4M | -11024.6% | -180.9% |
| FY2016 | $0 | -$7.6M | — | -$6.1M | — | -106.3% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Matinas BioPharma Holdings, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Matinas BioPharma Holdings, Inc. has historically struggled to out-earn its cost of capital, averaging just -38.9% ROIC.
Matinas BioPharma Holdings, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Matinas BioPharma Holdings, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-66.43 per share.